Clinical trial
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure…
NCT00117234 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117234 |
|---|---|
| Title | Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia |
| Official title | A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Congestive Heart Failure, Anemia |
| Intervention type | Drug |
| Interventions | darbepoetin alfa |
| Start date | Sep 1, 2002 |
| Completion | Jul 1, 2004 |
| First posted | Jul 6, 2005 |
| Last update posted | Dec 3, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: